Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG002 in HER2-positive Advanced Biliary Tract Cancer
NCT04837508Phase 2Unknown
- Sponsor
- Hangzhou Miracogen
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MRG002 in biliary tract cancer (BTC), sponsored by Hangzhou Miracogen. Status: unknown.
02
Drugs
MRG002
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04837508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04837508.